As the ASCO guidelines recommended, for HR+, HER2− tumors, NAC can be administered instead of adjuvant chemotherapy to any patient in whom the chemotherapy decision can be made without surgical pathology data and/or tumor-specific genomic testing [37]. Here, ERBB2 is linked to neoplasm.